**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## LISTING OF CLAIMS

1. (Currently Amended) A method for enhancing recovery by epithelial cells from ischemia by targeting ~~distinct~~ lesions, comprising:

contacting a lesion with a plurality of agents that act by performing two or more ~~an~~ actions selected from the group consisting of:

(i) inhibiting internalization of one or more intercellular junction proteins;

(ii) promoting activation of specific signaling events during short-term ischemia;

(iii) inhibiting degradation of proteins necessary for the maintenance of the polarized epithelial cell phenotype;

(iv) enhancing protein folding and assembly capacity in the ER and/or cytosol; and

(v) any combination of (i)-(iv).

2. (Previously presented) The method according to claim 1, wherein the inhibiting of the internalization comprises contacting the lesion with drugs or growth factors that specifically modulate signaling through a mechanism selected from the group consisting of $IP_3$-sensitive calcium stores, G-proteins, protein kinase C, and other kinases implicated in reassembly response during calcium switch.

3. (Previously presented) The method according to claim 1, wherein the promoting refers to facilitating the resorting of growth factor receptors to the cell surface thereby

enhancing the effectiveness of endogenous and/or exogenous growth factors administered after ischemic insult.

4. (Previously presented) The method according to claim 1, wherein the inhibiting degradation refers to prevention of proteolytic cleavage of proteins.

5. (Previously presented) The method according to claim 1, wherein an agent which upregulate cytoprotective chaperones comprises an inhibitor of proteasomes.

6. (Previously presented) The method according to claim 1, wherein one of the plurality of agents comprises tunicamycin.

7. (Previously presented) The method of claim 1, wherein intracellular membrane proteins are E-cadherin, claudin and/or occluding.

8. (Previously presented) The method of claim 1, wherein the plurality of agents includes at least two of the following members selected from the group consisting of a growth factor, a protein kinase C activator, a GTP binding protein activator, a proteasome inhibitor, a caspase inhibitor, an agent that upregulates cytoprotective chaperones, and an agent that modulates stress responses.

9. (Withdrawn) The method of claim 8, wherein the proteosome inhibitor is MG132 and/or lactocystin.

10. (Withdrawn) The method of claim 8, wherein the agent that upregulates cytoprotective chaperones is MG132 and/or lactocystin.

11. (Withdrawn) The method of claim 8, wherein the growth factor is selected from the group consisting of insulin-like growth factor, pleiotriphin, midkine, fibroblast growth factor, epidermal growth factor receptor ligands, melanocyte stimulating hormone, hepatocyte growth factor.

12. (Withdrawn) The method of claim 8, wherein the protein kinase C activator is a diacylglycerol analog.

13. (Withdrawn) The method of claim 8, wherein the GTP binding protein activator is selected from the group consisting of a nonhydrolyzable GTP analog, aluminum fluoride, lysophosphatidic acid and phenylphrine.

14. (Previously presented) The method of claim 8, wherein the agent that modulates stress responses is selected form the group consisting of tunicamycin and geldanomycin.